EFTA Document EFTA01457560

I I May 2015 Pharmaceuticals GlaxoSmithKline Newsflow IFiguna 5: Potential newsflow and catalysts Toning Event Etiecnption Mid-IS Competitor Potential approval of LAM/VtABA tiotropium/oladaterol for COPD Nov-15 Avodart US patent expiry 2H16 Brno Headline results from mortality/morbidity study (SUMMIT) 03-Nov-15 R&D Investor day to update on pharmaceutical and vaccine pipelines 4016 Mepolizumab US regulatory decision in severe asthma 2015 Mosquirix EMA approval decision on malaria vaccine 2015 Sartakumab Phase Ill data in rheumatoid arthritis IRA) 2015 Investigation Possible outcome of SFO investigation 2/115 HZ/su Data from trial of Herpes Zoster vaccine in the elderly 21115 Competitor Possible filing by Mytan for substitutible Advair generic 21116 Breo Results of SALFORD real world outcomes trial in COPO 2016 SNngrix File for regulatory approval for shingles vaccine 2016 Competitor First submission planned for Advair generic by Teva 21116 Advair Possible first US launch of Advair generics 2/116 Closed triple Results of Phase III trials of closed triple combo in COPD 2016 Competitor Expected launch ol I.V. reslizumab for severe asthma 2018 Competitor Expected launch of subcut reslizumab for severe asthma Mid-lb Competitor Potential approval of LAMIVLABA tiotropiumkiladaterol for COPD Nov-15 Avodart US patent expiry 2H16 Broo Headline results from mortalityhnorbidity Study (SUMMIT) souse- Past?* eve Deutsche Bank AG/London Page 7 CONFIDENTIAL — PURSUANT TO FED R CRIM. P. 6(e) DB-SDNY-0117157 CONFIDENTIAL SDNY_GM_00263341 EFTA01457560